Comparison of advanced stage mucinous epithelial ovarian cancer and serous epithelial ovarian cancer with regard to chemosensitivity and survival outcome: a matched case-control study

Abstract

Advanced stage mEOC patients have more platinum resistance disease and poorer survival outcome when compared to advanced stage sEOC. Therefore, novel chemotherapy strategies are warranted to improve survival outcome in patients with mEOC.

References

Page 1

	Year	Citations
Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer William P. McGuire, William J. Hoskins, Mark F. Brady, New England Journal of Medicine	1996	2.9K
Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Griffiths Ct PubMed Surgical OncologySurgical ResectionGross TumorGynecological SurgeryTumoral Pathology	1975	817
Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. G Omura, Mark F. Brady, Howard D. Homesley, Journal of Clinical Oncology Cancer ManagementGynecologyPathologyAdvanced Ovarian CarcinomaMetronomic Chemotherapy	1991	468
Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers John K. Chan, Deanna Teoh, Jessica M. Hu, Gynecologic Oncology Tumoral PathologyMedicineGynecologyPathologyCancer Prognosis	2008	452
Mucinous Epithelial Ovarian Cancer: A Separate Entity Requiring Specific Treatment Viviane Hess, Roger A’Hern, Nazar Nasiri, Journal of Clinical Oncology	2004	325
Advanced stage mucinous epithelial ovarian cancer: The Hellenic Cooperative Oncology Group experience Dimitrios Pectasides, George Fountzilas, Gerasimos Aravantinos, Gynecologic Oncology Tumoral PathologyGynecological SurgeryMedicinePathologyGynecology	2005	211
Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal Richard J. Zaino, Mark F. Brady, Subodh M. Lele, Cancer	2010	156
Clinicopathological characteristics of mucinous adenocarcinoma of the ovary Muneaki Shimada, Junzo Kigawa, Yoshihiro Ohishi, Gynecologic Oncology Tumoral PathologySurgical PathologyHistopathologyGynecologyPathology	2009	148
Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: Who benefits? Rongyu Zang, Zi‐Ting Li, Jie Tang, Cancer	2004	142
Natural history and outcome of mucinous carcinoma of the ovary Maria B. Schiavone, Thomas J. Herzog, Sharyn N. Lewin, American Journal of Obstetrics and Gynecology Surgical OncologyTumoral PathologyMedicineNatural HistoryGynecology	2011	115

Page 1